The packet lists no known genes and no inheritance pattern for this condition, and these fields are unknown in this packet rather than confirmed absent. The condition name specifies a BCR-ABL1-positive form, and the definition places it as an advanced phase of chronic myelogenous leukemia. The packet does not supply further information on cause or mechanism.

The packet does not list diagnostic methods. Its definition, adapted from WHO (2001), characterizes the phase by any of the following: blasts making up at least 20% of peripheral blood white cells or of nucleated cells in the bone marrow; an extramedullary proliferation of blasts; or large aggregates and clusters of blasts in a bone marrow biopsy specimen.

The packet lists one FDA record under approved treatments: nilotinib, approved through an NDA from the FDA's Center for Drug Evaluation and Research (CDER) on 2025-02-19, with market status ACTIVE. The packet does not state the indication for this record, so its specific use in blast phase disease is not described here. No other certified treatment information, such as foundational therapies, is supplied in this packet.

Prognosis is not certified in this packet, which supplies no natural history or prognosis source for this condition.

Active clinical trials for this condition are listed on ClinicalTrials.gov. The packet records 28 active records from a search on the condition name, and its intervention summary indicates that gene therapy trials are among them. One listed record, NCT07148947, is a Phase 2 study of pacritinib with azacitidine or decitabine as a bridge to allogeneic hematopoietic stem cell transplant in accelerated and blast phase myeloproliferative neoplasms, sponsored by the University of Washington, recruiting, from 2026-03-02 to 2028-12-31. The research digest classifies 193 publications, with Case Report / Case Series as the dominant type.